Head-to-head · Cost-Efficiency Index
Sesame Care vs Peter MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Sesame Care
People who specifically want FDA-approved brand-name medication (including the Wegovy pill or oral Rybelsus) from an established, verified marketplace and will budget for a two-part cost.
Visit Sesame CarePeter MD
Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Visit Peter MDThe verdict
Sesame Care takes it, leading the Cost-Efficiency Index 86 to 72. The widest real brand-name GLP-1 access on the board — a LegitScript- and BBB-recognized national marketplace running since 2018 that dispenses FDA-approved Wegovy, Zepbound, Ozempic, Mounjaro and Rybelsus, not compounded copies. Peter MD still earns a C — Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Sesame Care.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Sesame Care | Peter MD |
|---|---|---|
| Cost-Efficiency Index | 86/100 | 72/100 |
| Semaglutide / mo | $149/mo (brand) | $149/mo first-time (Level 1), $139/mo returning (Level 2) |
| Tirzepatide / mo | Brand (Zepbound) | $149 first month, then $249/mo billed quarterly |
| Semaglutide / yr (modeled) | — | $1,788 |
| Tirzepatide / yr (modeled) | — | $2,988 |
| Coverage | Nationwide | Varies by treatment — excluded in several states (marketing pages list AL/ID; the affiliate program's own disclosure is wider) |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Compounded only |
| Rank on the board | #6 | #44 |
Sesame Care
86/100Where the value is
- Widest brand-name formulary we list — Wegovy pen and pill, Zepbound, Ozempic, Mounjaro and oral Rybelsus, all FDA-approved rather than compounded
- Established national marketplace operating since 2018, with LegitScript certification and BBB recognition
- Wegovy pill starts around $149/mo, and oral routes are available for the needle-averse
The tradeoffs
- Two-part cost — the medication price is separate from a platform subscription, so the all-in monthly runs above the $149 headline
- A generalist telehealth marketplace, not a dedicated GLP-1 program
Peter MD
72/100Where the value is
- Broadest cross-category catalogue on this board under one account: TRT, ED, non-GLP-1 weight loss, GLP-1 (semaglutide/tirzepatide), men's hair loss and NAD+, plus sermorelin
- Physician-prescribed, nationwide telehealth brand operating since 2021 (Miami, FL HQ)
- Sermorelin ($585 for a 12-week supply, ~$195/mo) and NAD+ ($369 for an 8-10 week supply, ~$147-184/mo) sit in the same catalogue as the GLP-1 line for anyone consolidating multiple scripts
The tradeoffs
- Tirzepatide's $149 first-month rate steps up to $249/mo billed quarterly — the number that matters for budgeting is the renewal price, not the headline
- Semaglutide pricing depends on tier: $149/mo first-time (Level 1) vs $139/mo returning (Level 2), with different total costs ($447 vs $834) over different supply windows, so the all-in cost is not a single number
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.